The University of Chicago Header Logo

Mei-Yin Polley

Concepts (296)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Brain Neoplasms
23
2024
782
2.440
Why?
Glioblastoma
15
2024
265
2.420
Why?
Research Design
9
2024
599
1.890
Why?
Breast Neoplasms
9
2022
3011
1.370
Why?
Biomarkers, Tumor
12
2022
1549
1.310
Why?
Lymphoma, Large B-Cell, Diffuse
3
2020
154
1.210
Why?
Glioma
6
2023
294
1.100
Why?
Triple Negative Breast Neoplasms
4
2022
152
1.080
Why?
Biomarkers
5
2023
1767
0.920
Why?
Data Interpretation, Statistical
4
2021
299
0.920
Why?
Dacarbazine
10
2019
102
0.890
Why?
Models, Statistical
4
2017
576
0.720
Why?
Statistics as Topic
1
2021
234
0.700
Why?
Antineoplastic Agents
8
2021
2415
0.690
Why?
Clinical Trials as Topic
5
2024
1150
0.680
Why?
Sample Size
4
2017
128
0.670
Why?
Antineoplastic Combined Chemotherapy Protocols
11
2022
2566
0.660
Why?
Ki-67 Antigen
3
2021
66
0.650
Why?
Positron-Emission Tomography
1
2020
337
0.610
Why?
Prognosis
14
2021
3783
0.610
Why?
Tissue Array Analysis
2
2015
127
0.600
Why?
Receptor, ErbB-2
5
2022
246
0.580
Why?
Precision Medicine
4
2023
410
0.530
Why?
Humans
61
2024
89357
0.500
Why?
Epidemiologic Research Design
1
2014
22
0.480
Why?
Biological Specimen Banks
1
2014
65
0.460
Why?
Neoplasms
5
2023
3041
0.450
Why?
Disease-Free Survival
11
2021
1214
0.450
Why?
Biomedical Research
2
2017
398
0.450
Why?
Proportional Hazards Models
7
2020
851
0.440
Why?
Immunohistochemistry
3
2021
1799
0.420
Why?
Molecular Targeted Therapy
2
2013
286
0.400
Why?
Clinical Trials, Phase I as Topic
2
2014
156
0.380
Why?
Female
35
2022
46202
0.380
Why?
Kaplan-Meier Estimate
7
2020
860
0.380
Why?
Neoplasm Recurrence, Local
8
2023
1365
0.380
Why?
Clinical Trials, Phase II as Topic
2
2012
172
0.370
Why?
Maximum Tolerated Dose
1
2011
272
0.360
Why?
Computational Biology
1
2013
543
0.350
Why?
Neurosurgical Procedures
6
2011
232
0.350
Why?
Paraproteinemias
2
2020
15
0.340
Why?
Dose-Response Relationship, Drug
3
2019
1942
0.320
Why?
Lymphoma, Follicular
2
2019
73
0.310
Why?
Aged
24
2020
19165
0.300
Why?
Endpoint Determination
1
2007
61
0.290
Why?
Predictive Value of Tests
5
2017
1723
0.280
Why?
Oligodendroglioma
2
2022
45
0.280
Why?
Randomized Controlled Trials as Topic
3
2024
838
0.280
Why?
Aged, 80 and over
13
2020
6811
0.270
Why?
Middle Aged
25
2021
25974
0.270
Why?
Tumor Microenvironment
2
2021
463
0.270
Why?
Vincristine
3
2022
112
0.270
Why?
Adult
25
2020
26607
0.260
Why?
Young Adult
15
2020
6312
0.250
Why?
Cyclophosphamide
3
2020
302
0.250
Why?
Antibodies, Monoclonal, Humanized
3
2020
969
0.240
Why?
Radiotherapy, Adjuvant
4
2013
296
0.240
Why?
Prospective Studies
5
2023
4289
0.230
Why?
Treatment Outcome
17
2021
8241
0.220
Why?
Follow-Up Studies
9
2020
3666
0.220
Why?
Meningioma
1
2023
63
0.220
Why?
Meningeal Neoplasms
1
2023
67
0.220
Why?
Etoposide
2
2020
206
0.210
Why?
Prednisone
2
2020
259
0.210
Why?
Receptors, Estrogen
2
2021
393
0.210
Why?
Male
25
2020
42411
0.200
Why?
Chemotherapy, Adjuvant
5
2019
487
0.200
Why?
Controlled Clinical Trials as Topic
1
2021
22
0.200
Why?
Combined Modality Therapy
10
2020
1719
0.200
Why?
British Columbia
1
2021
8
0.190
Why?
Medical Oncology
2
2023
383
0.190
Why?
Neurology
1
2021
74
0.180
Why?
Fluorine Radioisotopes
1
2020
25
0.180
Why?
Cyclin D1
1
2020
84
0.170
Why?
Rituximab
1
2020
119
0.170
Why?
Bendamustine Hydrochloride
1
2019
11
0.170
Why?
Internal Medicine
1
2023
355
0.170
Why?
Fluorodeoxyglucose F18
1
2020
142
0.170
Why?
Disease Progression
6
2018
1489
0.170
Why?
Monosomy
1
2019
12
0.170
Why?
Bortezomib
1
2019
82
0.160
Why?
Haploidy
1
2019
32
0.160
Why?
Radiopharmaceuticals
1
2020
193
0.160
Why?
Capecitabine
1
2019
98
0.160
Why?
Astrocytoma
2
2010
82
0.160
Why?
Quality of Life
3
2014
1668
0.160
Why?
Reproducibility of Results
5
2023
2758
0.160
Why?
Chromosomes, Human, Pair 17
1
2019
111
0.160
Why?
Computer Simulation
2
2014
1097
0.160
Why?
Magnetic Resonance Imaging
7
2011
3448
0.150
Why?
Hodgkin Disease
1
2019
181
0.150
Why?
Genomics
2
2013
762
0.150
Why?
Antimetabolites, Antineoplastic
1
2019
244
0.150
Why?
Survival Analysis
3
2020
1534
0.140
Why?
Radiosurgery
1
2020
288
0.140
Why?
Lymphocytes, Tumor-Infiltrating
1
2017
131
0.140
Why?
DNA Repair Enzymes
2
2013
55
0.130
Why?
Tumor Suppressor Protein p53
1
2019
414
0.130
Why?
Neoplasm Staging
6
2021
2018
0.130
Why?
Retrospective Studies
9
2019
9057
0.130
Why?
CD4-Positive T-Lymphocytes
1
2019
445
0.130
Why?
Mutation
2
2019
4143
0.120
Why?
Karnofsky Performance Status
2
2011
40
0.120
Why?
Multiple Myeloma
1
2019
330
0.120
Why?
Indoles
3
2011
314
0.120
Why?
Antineoplastic Agents, Alkylating
3
2011
138
0.120
Why?
Survival Rate
6
2019
1901
0.120
Why?
Risk Assessment
1
2022
2303
0.120
Why?
Doxorubicin
3
2019
301
0.120
Why?
Monte Carlo Method
1
2014
186
0.120
Why?
DNA Modification Methylases
1
2013
28
0.110
Why?
T-Lymphocytes
1
2020
1224
0.110
Why?
Laboratories
1
2013
44
0.110
Why?
Indazoles
1
2013
67
0.110
Why?
Drug Discovery
1
2014
107
0.110
Why?
Logistic Models
2
2014
1213
0.110
Why?
Methylation
1
2013
268
0.100
Why?
TOR Serine-Threonine Kinases
2
2011
187
0.100
Why?
Interleukin-6
1
2013
261
0.100
Why?
Sulfotransferases
1
2012
19
0.100
Why?
Receptor, Platelet-Derived Growth Factor alpha
1
2012
12
0.100
Why?
Quinazolines
1
2013
221
0.100
Why?
Phosphatidylinositol 3-Kinases
2
2011
267
0.100
Why?
Age Factors
2
2019
1870
0.100
Why?
Gliosarcoma
1
2011
7
0.100
Why?
Genetic Variation
1
2018
1374
0.100
Why?
Ependymoma
1
2011
18
0.100
Why?
Tumor Suppressor Proteins
1
2013
290
0.100
Why?
Sulfonamides
1
2013
318
0.090
Why?
Hydroxamic Acids
1
2011
51
0.090
Why?
Pyrimidines
1
2013
374
0.090
Why?
Radiation-Sensitizing Agents
1
2011
97
0.090
Why?
Inositol
1
2010
16
0.090
Why?
Supratentorial Neoplasms
1
2010
10
0.090
Why?
Histone Deacetylase Inhibitors
1
2011
92
0.090
Why?
Exotoxins
1
2010
20
0.090
Why?
Gyrus Cinguli
1
2010
46
0.090
Why?
Lung Neoplasms
2
2013
2362
0.090
Why?
ErbB Receptors
1
2013
501
0.090
Why?
Spinal Neoplasms
1
2010
49
0.090
Why?
Interleukin-13
1
2010
38
0.090
Why?
Craniotomy
1
2010
88
0.090
Why?
Genes, p16
1
2010
11
0.090
Why?
Health Services Needs and Demand
1
2011
103
0.090
Why?
Catheters
1
2010
76
0.090
Why?
Diffusion Tensor Imaging
1
2010
71
0.090
Why?
Central Nervous System Neoplasms
1
2010
85
0.080
Why?
Paclitaxel
2
2022
479
0.080
Why?
Magnetic Resonance Spectroscopy
1
2010
312
0.080
Why?
Caregivers
1
2011
160
0.080
Why?
Carcinoma, Renal Cell
1
2013
437
0.080
Why?
Chemoradiotherapy
1
2011
309
0.080
Why?
Immunologic Factors
1
2010
171
0.080
Why?
Proto-Oncogene Proteins B-raf
1
2010
146
0.080
Why?
Immunotherapy
1
2014
682
0.080
Why?
PTEN Phosphohydrolase
1
2009
136
0.080
Why?
Gene Deletion
1
2010
342
0.080
Why?
Wound Healing
1
2010
359
0.080
Why?
Mutation, Missense
1
2010
277
0.080
Why?
Neoadjuvant Therapy
2
2022
377
0.080
Why?
In Situ Hybridization, Fluorescence
2
2019
354
0.080
Why?
Image Processing, Computer-Assisted
2
2011
1242
0.070
Why?
Kidney Neoplasms
1
2013
638
0.070
Why?
Pharmacogenetics
1
2011
443
0.070
Why?
Inflammation
1
2013
972
0.070
Why?
Clinical Trials, Phase III as Topic
2
2022
175
0.070
Why?
Intracellular Signaling Peptides and Proteins
1
2009
387
0.070
Why?
Neuroblastoma
1
2011
395
0.070
Why?
DNA Methylation
1
2011
657
0.070
Why?
Bevacizumab
2
2022
289
0.070
Why?
Cerebral Cortex
1
2010
589
0.060
Why?
Adolescent
6
2019
9263
0.060
Why?
Carcinoma, Non-Small-Cell Lung
1
2013
1120
0.060
Why?
Neoplasm Grading
2
2019
374
0.060
Why?
Antibodies, Monoclonal
1
2010
1412
0.060
Why?
Cell Line, Tumor
3
2019
2558
0.060
Why?
Gene Expression Regulation
1
2012
1976
0.050
Why?
Odds Ratio
2
2018
683
0.050
Why?
Lomustine
1
2022
26
0.050
Why?
Procarbazine
1
2022
40
0.050
Why?
Signal Transduction
2
2012
3385
0.050
Why?
International Cooperation
2
2013
125
0.050
Why?
Cell Proliferation
3
2012
1652
0.050
Why?
Immunoenzyme Techniques
2
2011
306
0.050
Why?
Risk Factors
1
2011
5499
0.050
Why?
Carboplatin
1
2022
312
0.050
Why?
Analysis of Variance
2
2014
899
0.050
Why?
Neoplasm, Residual
1
2022
181
0.050
Why?
Information Dissemination
1
2021
114
0.050
Why?
Trastuzumab
1
2020
74
0.040
Why?
Postoperative Complications
1
2010
2284
0.040
Why?
DNA, Neoplasm
2
2011
268
0.040
Why?
Statistics, Nonparametric
2
2011
306
0.040
Why?
Vinblastine
1
2019
108
0.040
Why?
Bleomycin
1
2019
102
0.040
Why?
Tumor Necrosis Factor Receptor Superfamily, Member 7
1
2019
3
0.040
Why?
Blotting, Western
2
2011
794
0.040
Why?
Cohort Studies
3
2010
2872
0.040
Why?
Societies, Medical
1
2023
575
0.040
Why?
B7-H1 Antigen
1
2021
274
0.040
Why?
Mice, Nude
2
2011
815
0.040
Why?
Karyotype
1
2019
34
0.040
Why?
Chromosome Banding
1
2018
74
0.040
Why?
CD28 Antigens
1
2019
90
0.040
Why?
Methotrexate
1
2019
250
0.040
Why?
Radiotherapy
2
2011
333
0.040
Why?
Genes, myc
1
2018
39
0.040
Why?
Gene Expression Profiling
1
2023
1431
0.040
Why?
Gene Rearrangement
1
2018
173
0.040
Why?
Fluorouracil
1
2019
561
0.040
Why?
Drug Administration Schedule
1
2019
895
0.040
Why?
Programmed Cell Death 1 Receptor
1
2019
171
0.040
Why?
Time Factors
2
2020
5338
0.040
Why?
Remission Induction
1
2019
740
0.040
Why?
Chromosome Aberrations
1
2018
390
0.040
Why?
Receptors, Progesterone
1
2017
174
0.030
Why?
Alleles
1
2020
1135
0.030
Why?
Estrogen Receptor alpha
1
2017
148
0.030
Why?
Neoplasm Metastasis
1
2020
1109
0.030
Why?
Transcriptome
1
2020
630
0.030
Why?
Neoplasm Invasiveness
1
2017
576
0.030
Why?
Confidence Intervals
1
2014
225
0.030
Why?
Cells, Cultured
1
2019
2884
0.030
Why?
National Cancer Institute (U.S.)
1
2013
73
0.030
Why?
Survival
1
2013
21
0.030
Why?
Evaluation Studies as Topic
1
2013
270
0.030
Why?
Child, Preschool
2
2011
3731
0.030
Why?
Checklist
1
2013
61
0.030
Why?
High-Throughput Screening Assays
1
2013
58
0.030
Why?
Mice
3
2012
11761
0.030
Why?
Specimen Handling
1
2013
102
0.030
Why?
Bayes Theorem
1
2014
370
0.030
Why?
Guidelines as Topic
1
2013
160
0.030
Why?
Animals
4
2014
27371
0.030
Why?
Sulfatases
1
2012
3
0.030
Why?
Heparan Sulfate Proteoglycans
1
2012
21
0.030
Why?
Observer Variation
1
2013
610
0.020
Why?
Polymorphism, Single Nucleotide
1
2020
2401
0.020
Why?
Chemoradiotherapy, Adjuvant
1
2011
35
0.020
Why?
Tumor Stem Cell Assay
1
2011
37
0.020
Why?
Gamma Rays
1
2011
73
0.020
Why?
Acetylation
1
2011
132
0.020
Why?
Genetic Predisposition to Disease
1
2020
2340
0.020
Why?
Histone Deacetylases
1
2011
70
0.020
Why?
Sensation Disorders
1
2010
24
0.020
Why?
Luminescent Proteins
1
2011
144
0.020
Why?
Choline
1
2010
24
0.020
Why?
Intraoperative Period
1
2010
90
0.020
Why?
Movement Disorders
1
2010
44
0.020
Why?
Software
1
2014
665
0.020
Why?
Drug Synergism
1
2011
306
0.020
Why?
Neuronavigation
1
2010
22
0.020
Why?
Risk Management
1
2010
43
0.020
Why?
Muscle Weakness
1
2010
60
0.020
Why?
Forkhead Transcription Factors
1
2011
171
0.020
Why?
Adaptation, Psychological
1
2011
166
0.020
Why?
Tomography, X-Ray Computed
1
2020
2661
0.020
Why?
Functional Laterality
1
2010
200
0.020
Why?
Activities of Daily Living
1
2011
207
0.020
Why?
Tumor Burden
1
2011
308
0.020
Why?
Perfusion
1
2010
236
0.020
Why?
Sulfites
1
2009
31
0.020
Why?
Cell Survival
1
2012
983
0.020
Why?
Nervous System Diseases
1
2010
162
0.020
Why?
Xenograft Model Antitumor Assays
1
2011
470
0.020
Why?
Tumor Cells, Cultured
1
2011
1057
0.020
Why?
Microsurgery
1
2010
88
0.020
Why?
Polymerase Chain Reaction
1
2011
922
0.020
Why?
Flow Cytometry
1
2011
691
0.020
Why?
Gene Silencing
1
2010
178
0.020
Why?
Cytokines
1
2013
803
0.020
Why?
Serine
1
2009
104
0.020
Why?
Gene Dosage
1
2010
208
0.020
Why?
Child
2
2011
7174
0.020
Why?
Linear Models
1
2010
421
0.020
Why?
Histones
1
2011
329
0.020
Why?
Drug Therapy, Combination
1
2011
784
0.020
Why?
Sickness Impact Profile
1
2008
26
0.020
Why?
Recombinant Fusion Proteins
1
2010
565
0.020
Why?
Mice, Transgenic
1
2012
1574
0.020
Why?
Enzyme Inhibitors
1
2011
645
0.020
Why?
Patient Satisfaction
1
2011
461
0.020
Why?
Emotions
1
2011
349
0.020
Why?
Brain Mapping
1
2010
564
0.020
Why?
Case-Control Studies
1
2011
1862
0.020
Why?
Phosphorylation
1
2009
1132
0.020
Why?
Models, Biological
1
2013
1765
0.020
Why?
Sensitivity and Specificity
1
2010
2015
0.020
Why?
Image Interpretation, Computer-Assisted
1
2010
688
0.020
Why?
Longitudinal Studies
1
2008
1072
0.020
Why?
Infant
1
2011
3160
0.010
Why?
Apoptosis
1
2011
1717
0.010
Why?
Gene Expression Regulation, Neoplastic
1
2009
1265
0.010
Why?
Surveys and Questionnaires
1
2011
2624
0.010
Why?
Brain
1
2011
2285
0.010
Why?
United States
1
2013
6989
0.010
Why?
Polley's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (296)
Explore
_
Co-Authors (13)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_